Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors

OBJECTIVE: In the ORAL (Oral Rheumatoid Arthritis triaL) Surveillance study of patients with rheumatoid arthritis aged ≥50 years with ≥1 additional cardiovascular risk factor, incidence of pulmonary embolism was higher with tofacitinib 10 mg two times per day than with tumour necrosis factor inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Weitz, Jeffrey I, Szekanecz, Zoltán, Charles-Schoeman, Christina, Vranic, Ivana, Sahin, Burak, Paciga, Sara A, Wang, Zhenyu, Hyde, Craig, Martin, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639150/
https://www.ncbi.nlm.nih.gov/pubmed/36323490
http://dx.doi.org/10.1136/rmdopen-2022-002571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639150/
https://www.ncbi.nlm.nih.gov/pubmed/36323490
http://dx.doi.org/10.1136/rmdopen-2022-002571

Ejemplares similares